Last deal

$11.5M

Amount

Post-IPO Equity

Stage

28.06.2024

Date

3

all rounds

$200.61M

Total amount

date founded

Financing round

General

About Company
Elicio Therapeutics develops immuno-tumor vaccines to treat cancer.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Elicio, Vedantra Pharmaceuticals

founded date

01.01.2011

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Elicio Therapeutics is a pharmaceutical research company that combines materials science and immunology to engineer potent vaccines and immuno-therapies for aggressive cancers. Their Amphiphile platform delivers immunogens directly to the lymphatic system, enhancing the body's immune defenses to defeat cancer and stop its recurrence. The company's lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the Amphiphile technology invented and developed at the Massachusetts Institute of Technology. Preclinical studies have shown that Elicio's Amphiphile vaccines target and concentrate in the lymph nodes, resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Argos Therapeutics

Argos Therapeutics

Argos Therapeutics develops personalized immunotherapies for cancer and infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Durham, NC, USA

total rounds

14

total raised

$282.05M
Affimed

Affimed

Affimed is a clinical-stage biopharmaceutical company focused on targeted cancer immunotherapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Heidelberg, Germany

total rounds

14

total raised

$513.93M
Tizona Therapeutics

Tizona Therapeutics

Tizona Therapeutics is developing treatments for cancer and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

South San Francisco, CA, USA

total rounds

3

total raised

$370M
IMV

IMV

IMV Inc. is developing a targeted immune therapy for cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Dartmouth, NS, Canada

total rounds

4

total raised

$88.6M

Financials

Funding Rounds
17
3

Number of Funding Rounds

$200.61M

Money Raised

Their latest funding was raised on 28.06.2024. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
28.06.2024
$11.5M
22.12.2023
$7M
Gastro-Intestinal Research Foundation

Gastro-Intestinal Research Foundation

For more than 50 years, we have devoted ourselves to making life better for patients and families living with digestive diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Non-Profit

Location

Chicago, IL, USA

count Of Investments

5
Co-Investors
Investors
8
7

Number of lead investors

8

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Debt Financing
Yes
Venture - Series Unknown
Gastro-Intestinal Research Foundation

Gastro-Intestinal Research Foundation

For more than 50 years, we have devoted ourselves to making life better for patients and families living with digestive diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Non-Profit

Location

Chicago, IL, USA

count Of Investments

5
Angion Biomedica

Angion Biomedica

Angion Biomedica is a clinical-stage biopharmaceutical company focused on restoring organs, with a particular focus on renal disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Uniondale, NY, USA

total rounds

7

total raised

$176.27M

count Of Investments

1
Access BridgeGap Ventures

Access BridgeGap Ventures

Access Industries is a global industrial group with long-term investments.

Sector

General Industrials

Subsector

Diversified Industrials

Keywords

Industrial, Manufacturing

Location

Cambridge, MA, USA

count Of Investments

6

count Of Exists

1
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Angion Biomedica acquired by Elicio Therapeutics

Angion Biomedica acquired by Elicio Therapeutics

acquirer

Elicio Therapeutics
Elicio Therapeutics

date

01.01.2023

type

Acquisition
Angion Biomedica

Angion Biomedica

Angion Biomedica is a clinical-stage biopharmaceutical company focused on restoring organs, with a particular focus on renal disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Uniondale, NY, USA

total rounds

7

total raised

$176.27M

count Of Investments

1

People

Founders
3

Satish Jindal

current job

Elicio Therapeutics
Elicio Therapeutics

organization founded

1

Satish Jindal

Darrell Irvine
Darrell Irvine

Darrell Irvine

Darrell Irvine joined MIT as Professor in 2002.Darrell Irvine, Ph.D. Professor, Departments of Biological Engineering and Materials Science & Engineering Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology Ragon Institute of MGH, MIT, and Harvard Investigator, Howard Hughes Medical Institute.Biography: Darrell Irvine, Ph.D., is a Professor at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute. He also serves on the steering committee of the Ragon Institute of MGH, MIT, and Harvard. His research is focused on the application of engineering tools to problems in cellular immunology and the development of new materials for vaccine and drug delivery. Current efforts are focused on problems related to vaccine development for HIV and malaria, and immunotherapy of cancer. This interdisciplinary work has been recognized in numerous awards, including a Beckman Young Investigator award, an NSF CAREER award, selection for Technology Review’s ‘TR35’, election as a Fellow of the Biomedical Engineering Society, and appointment as an investigator of the Howard Hughes Medical Institute. He is the author of over 70 publications, reviews, and book chapters and an inventor on numerous patents.

current job

Ankyra
Ankyra

organization founded

3

Darrell Irvine

Satish Jindal
Satish Jindal

Satish Jindal

Satish Jindal, PhD, is BioMotiv’s CEO. Most recently, Dr. Jindal served as CEO of Allied-Bristol Life Sciences (ABLS). Prior to ABLS, he served as a Vice President at Bristol-Myers Squibb (BMS). Dr. Jindal has extensive experience in founding and building biotechnology companies, including Elicio Therapeutics Inc., an immunotherapy company that he co-founded based on intellectual property from the Koch Institute at the Massachusetts Institute of Technology (MIT); AntolRx, an immune tolerance company spun out from Harvard; Verastem Inc, a NASDAQ-listed Oncology company that he co-founded with researchers from the Whitehead Institute, the Broad Institute and MIT; and NeoGenesis Inc., a drug discovery company, he co-founded and served as its CEO, before its acquisition by Schering-Plough (now Merck) in 2005. He also served as Vice President and Site Head at Schering-Plough Research Institute in Cambridge, Massachusetts, and worked in Business Development at UCB Pharma in the UK. Dr. Jindal completed his postdoctoral work at Whitehead Institute for Biomedical Research at MIT and McMaster University in Hamilton, Ontario, Canada. He obtained a PhD in Biochemistry from Punjab University in India.

current job

Advent Life Sciences
Advent Life Sciences

Satish Jindal

Employee Profiles
9
Joy Seymour

Joy Seymour

Vice President, Head of Regulatory Affairs

Peter C. DeMuth

Peter C. DeMuth

Chief Scientific Officer

Christopher Haqq

Christopher Haqq

Executive Vice President, Head of Research & Development

Daniel Geffken

Daniel Geffken

Interim Chief Financial Officer and Director

Darrell Irvine

Darrell Irvine

Co-Founder, SAB member

James Moon

James Moon

Director

Robert Connelly

Robert Connelly

CEO

George Siber

George Siber

Director

Activity

Recent News
11
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month